Richard Lorraine
Internal Medicine · Harleysville, PANPI 1528052347
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,431 and has fallen 71.9% since, to $402 in 2023.
Across 229 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$743
- Novo Nordisk$625
- Lilly USA, LLC$398
- Merck$289
- AstraZeneca$286
- Astellas Pharma US Inc$209
- plus $1K from 25 others
Across 307 payments — averaging $845.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$243K
- AstraZeneca$10K
- Kowa Research Institute, Inc.$4K
- Shionogi Inc$2K
What the payments were for
- Food & beverage$3,814100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $743 |
| Novo Nordisk | 41 | $625 |
| Lilly USA, LLC | 25 | $398 |
| Merck | 19 | $289 |
| AstraZeneca | 19 | $286 |
| Astellas Pharma US Inc | 13 | $209 |
| GSK | 11 | $190 |
| Amarin Pharma, Inc. | 9 | $149 |
| Biohaven Pharmaceuticals, Inc. | 7 | $121 |
| Pfizer | 7 | $102 |
| Johnson & Johnson | 6 | $96 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Abbott | 4 | $57 |
| Bayer | 3 | $54 |
| Exact Sciences | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Boehringer Ingelheim | 3 | $46 |
| Dexcom, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $22 |
| Novartis | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Intra-sana Laboratories | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$3,817 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 17 | $375 |
| Losartan Potassium | 14 | $240 |
| Atorvastatin Calcium | 18 | $181 |
| Levothyroxine Sodium | 21 | $175 |
| Simvastatin | 11 | $111 |
| Metformin Hcl | 11 | $98 |
| Hydrochlorothiazide | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Harleysville
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.